These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28073680)

  • 1. Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B
    Baldi M; Behera D; Kaur J; Kapoor R; Singh N
    Clin Lung Cancer; 2017 Jul; 18(4):432-435. PubMed ID: 28073680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
    Singh N; Baldi M; Kaur J; Muthu V; Prasad KT; Behera D; Bal A; Gupta N; Kapoor R
    Cancer; 2019 Jul; 125(13):2203-2212. PubMed ID: 30825389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
    Takagi Y; Hosomi Y; Nagamata M; Watanabe K; Takahashi S; Nakahara Y; Yomota M; Sunami K; Okuma Y; Shimokawa T; Okamura T
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):559-64. PubMed ID: 26821156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer.
    Takagi Y; Hosomi Y; Sunami K; Nakahara Y; Okuma Y; Yomota M; Shimokawa T; Nagamata M; Iguchi M; Okamoto H; Okamura T; Shibuya M
    Oncologist; 2014 Nov; 19(11):1194-9. PubMed ID: 25260366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
    Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
    Schlei Z; Tan W; Faber MG; Chen H; Meagher A; Dy GK
    Clin Lung Cancer; 2018 Nov; 19(6):467-475. PubMed ID: 30369425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
    Minchom A; Mak D; Gunapala R; Walder D; Kumar R; Yousaf N; Hodgkiss A; Bhosle J; Popat S; O'Brien MER
    PLoS One; 2019; 14(11):e0225509. PubMed ID: 31765437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.
    Stoffregen CC; Odin EA; Carlsson GU; Kurlberg GK; Björkqvist HG; Tångefjord MT; Gustavsson BG
    Anticancer Drugs; 2016 Jun; 27(5):439-46. PubMed ID: 26825869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy].
    Zeng X; Zhou C; Ouyang M; Qin Y; Yang H; Peng Y; Liu S
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):868-72. PubMed ID: 26887521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy.
    Singh N; Aggarwal AN; Kaur J; Behera D
    Am J Clin Oncol; 2017 Feb; 40(1):75-82. PubMed ID: 25089530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Plasma Homocysteine Level Assessment and Timing of Folate/B12 Supplementation Prior to Initiation of Pemetrexed-Based Chemotherapy for Nonsquamous Non-Small Cell Lung Cancer Patients: An Irrelevant Investigation, an Unnecessary Delay, or Both?
    Singh N; Maturu VN; Behera D
    Oncologist; 2015 Jul; 20(7):e21. PubMed ID: 26069280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
    Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells.
    Yang TY; Chang GC; Hsu SL; Huang YR; Chiu LY; Sheu GT
    Biomed Res Int; 2013; 2013():389046. PubMed ID: 23984356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous route for folate supplementation in a patient with celiac disease treated by pemetrexed-based chemotherapy for non-small-cell lung cancer.
    Beaurain M; Rioufol C; Vantard N; Teixeira A; Baudouin A; Herledan C; Souquet PJ; Couraud S; Ranchon F
    J Oncol Pharm Pract; 2023 Apr; 29(3):750-754. PubMed ID: 35918825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
    Chiappori A; Bepler G; Barlesi F; Soria JC; Reck M; Bearz A; Barata F; Scagliotti G; Park K; Wagle A; Liepa AM; Zhao YD; Chouaki N; Iscoe N; von Pawel J
    J Thorac Oncol; 2010 Mar; 5(3):369-75. PubMed ID: 20090562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
    Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
    Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.
    Bagley SJ; Vitale S; Zhang S; Aggarwal C; Evans TL; Alley EW; Cohen RB; Langer CJ; Blair IA; Vachani A; Whitehead AS
    Clin Lung Cancer; 2017 Mar; 18(2):e143-e149. PubMed ID: 27863923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
    Socinski MA; Raju RN; Neubauer M; Smith DA; Richards DA; Savin M; Ruxer RL; Reynolds CH; Zhan F; Bromund JL; Chen R; Obasaju C
    J Thorac Oncol; 2008 Nov; 3(11):1308-16. PubMed ID: 18978567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.